AC Immune
ACIU
15 hedge funds and large institutions have $110M invested in AC Immune in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 6 closing their positions.
21% more capital invested
Capital invested by funds: $90.4M → $110M (+$19.4M)
0.94% less ownership
Funds ownership: 18.06% → 17.12% (-0.94%)
12% less funds holding
Funds holding: 17 → 15 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.42M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$350K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$145K |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$103K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$85.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JG
Jefferies Group
New York
|
-$6.41M |
| 2 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$4.84M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$540K |
| 4 |
LBC
Lawrence B. Cohen
|
-$177K |
| 5 |
Renaissance Technologies
New York
|
-$177K |
ACIU Hedge Fund Activity: Q3 2017 in Review
15 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q3 2017, worth a combined $110M — up 21% from $90.4M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ACIU and 4 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Fidelity Investments, adding an estimated $6.42M. The largest seller was Jefferies Group, exiting entirely with an estimated $6.41M sold.
- 15 institutional investors held AC Immune (ACIU) as of Q3 2017, down from 17 in Q2 2017.
- Funds reported $110M of AC Immune stock for Q3 2017, up 21% quarter-over-quarter.
- 4 funds opened new AC Immune positions in Q3 2017 and 6 closed out, a net change of -2 holders.
- The largest AC Immune buyer in Q3 2017 was Fidelity Investments, an estimated $6.42M added.
- The largest AC Immune seller in Q3 2017 was Jefferies Group, an estimated $6.41M sold.
Based on aggregated 13F filings for Q3 2017.